SEC – ‘UPLOAD’ from 3/19/20 re: Aclaris Therapeutics, Inc. – ‘TEXT-EXTRACT’

On:  Thursday, 3/19/20, at 12:46pm ET   ·   Delayed-Release:  Filing ¶  –  Release Delayed to:  5/28/20   ·   Accession #:  0-20-2443

in

this entire Filing. an “Entity” Search.

Show

Documents searched

and

each “hit”. the 1st “hit”.

↓↑Hints

Delayed-Release Comment or Other Letter from the SEC
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: LETTER      Comment or Other Letter from the SEC                 PDF     32K 
 2: TEXT-EXTRACT  Comment or Other Letter from the SEC (PDF Text)      1      6K 

‘TEXT-EXTRACT’   —   Comment or Other Letter from the SEC (PDF Text)

                                                      March 19, 2020

Frank Ruffo                                                                     
Chief Financial Officer                                                         
Aclaris Therapeutics, Inc.                                                      
640 Lee Road, Suite 200                                                         
Wayne, PA 19087                                                                 

Re: Aclaris Therapeutics, Inc.                                    
Registration Statement on Form S-3                        
Filed March 13, 2020                                      
File No. 333-237163                                       

Dear Mr. Ruffo:                                                                 

      This is to advise you that we have not reviewed and will not review your
registration                                                                    
statement.                                                                      

      Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you                                                                   
that the company and its management are responsible for the accuracy and        
adequacy of their                                                               
disclosures, notwithstanding any review, comments, action or absence of action  
by the staff.                                                                   

    Please contact William Mastrianna, Attorney-Adviser, at (202) 551-3778
with any                                                                        
questions.                                                                      

                                                  Sincerely,

                                                   Division of
Corporation Finance                                                             
                                                      Office of Life
Sciences                                                                        
cc:    Mark Ballantyne                                                          

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘UPLOAD’ Filing		Date		Other Filings
Release Delayed to:		5/28/20		CORRESP,  UPLOAD
Filed on:		3/19/20		UPLOAD
		3/13/20		8-K,  S-3,  UPLOAD
				List all Filings

1 Previous Filing that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/13/20  Aclaris Therapeutics, Inc.        S-3                    7:1.5M                                   Toppan Merrill/FA